Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses

2003 ◽  
Vol 69 (3) ◽  
pp. 313-323 ◽  
Author(s):  
Vladimir P. Chulanov ◽  
German A. Shipulin ◽  
Stephan Schaefer ◽  
Wolfram H. Gerlich
Keyword(s):  
Hepatitis B ◽  
Acute Hepatitis ◽  
Hbv Dna ◽  
Hepatitis Viruses ◽  
Acute Hepatitis B ◽  
Kinetics Of

scholarly journals The dynamics of HCV DNA and HBsAg levels in acute hepatitis B patients in monoinfection and coinfection of other hepatitis viruses

2016 ◽  
Vol 21 (2) ◽  
pp. 74-81
Author(s):  
Vladimir P. Chulanov ◽  
E. Yu Kostygova ◽  
D. S Kostyushev ◽  
D. Glebe ◽  
G. A Shipulin ◽  
...  
Keyword(s):  
Viral Load ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
Half Life ◽  
Hbv Dna ◽  
Serum Samples ◽  
Hepatitis Viruses ◽  
Hepatitis D ◽  
Dna Elimination ◽  
Acute Hepatitis B

Introduction Changes in the levels of DNA of hepatitis B virus (HBV) infection and the quantitative content of the surface antigen (HBsAg) in acute hepatitis B, as well as the concomitant co-injection of other hepatitis viruses have been insufficiently studied so far. Materials and Methods In 21 patients with acute HBV monoinfection and 27 patients with co-infection of HBV + HCV and/ or HDV three to four serum samples were withdrawn with interval of 6-10 days and the dynamics of HBV viral load and concentration of HBsAg was examined. Results Logarithm of the concentration of DNA HBV was established to decrease from 4.0 ± 0.65 to 3.0 ± 0.59, to 2.5 ± 0.47, to 1.9 ± 0.65 (IU /ml, M ± s), the half-life of DNA HBV was increased from 1.6 days at baseline to 4 days to the end of the study. The decline of the HBsA concentration proceeded much slower: from 38 to 23, 12, 3.8 pg/ml. Half-life period of HBsAg accounted of 8 days at the beginning and 5.7 days at the end of the study, however, in 11 patients there was observed rapid elimination of HBsAg and disappearance of HBV DNA. Conclusion The fact of co-infection with hepatitis C virus (HCV) had no significant effect on the dynamics of HBV DNA and HBsAg levels. In patients infected with Hepatitis D virus (HDV) HBV viral load was significantly lower, and the concentration of HBsAg, by contrast, is significantly higher than in acute monoinfection with HBV. Thus, in acute hepatitis B DNA elimination occurs much faster than the elimination of HBsAg. In addition, in co-infection HDV inhibits replication of HBV, but at the same time stimulates the expression of HBsAg. The obtained data should be considered in the interpretation of laboratory tests in patients with acute hepatitis B, both in the earlier period, and at follow-up.

Serological assessment of HBcAg and HBV DNA: its prognostic relevance in acute hepatitis B

2008 ◽  
Vol 7 (5) ◽  
pp. 298-305 ◽  
Author(s):  
B. Möller ◽  
U. Hopf ◽  
S. Pöschke ◽  
M. Alexander ◽  
B. Friedrich-Jähnicke ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Acute Hepatitis ◽  
Hbv Dna ◽  
Prognostic Relevance ◽  
Acute Hepatitis B

scholarly journals Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff.

1997 ◽  
Vol 8 (9) ◽  
pp. 1443-1447
Author(s):  
M Cabrerizo ◽  
J Bartolomé ◽  
P De Sequera ◽  
C Caramelo ◽  
V Carreño
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hemodialysis Patients ◽  
Hbv Dna ◽  
Staff Members ◽  
B Virus ◽  
Acute Hepatitis B

Patients undergoing chronic hemodialysis, as well as dialysis staff members, are at high risk of infection with hepatitis B virus (HBV). We have analyzed by PCR the presence of HBV DNA in serum and peripheral blood mononuclear cells (PBMC) from 33 hepatitis B surface antigen (HBsAg)-negative hemodialysis patients and 24 dialysis unit staff members; eight of the 24 staff members had an acute hepatitis B resolved 13 to 21 yr before. HBV DNA was detected in serum of 19 (58%) patients (12 of 17 with and 7 of 16 without anti-HBV antibodies). HBV DNA was found in PBMC of 18 (54%) patients (13 of 17 with and 5 of 16 without anti-HBV antibodies). In the staff members, serum HBV DNA was found only in the individuals who suffered a previous acute hepatitis (P < 0.005). HBV DNA was detected in PBMC of four of six staff members (all with previous acute hepatitis). In two HBV DNA-positive PBMC samples, viral RNA was detected by reverse transcription-PCR. To ascertain whether the HBV DNA detected in serum was encapsulated, seven HBV DNA-positive serum samples were digested with DNase before PCR. After treatment, HBV DNA remained detectable in four cases. In conclusion, HBV DNA in serum and PBMC is detectable in a high proportion of HBsAg-negative hemodialysis patients and may persist several years after a resolved acute hepatitis B. The viral DNA is encapsulated and remains transcriptionally active in PBMC. In the anti-HBs-negative patients, HBV DNA is, at the present time, the only means for diagnosing a past HBV hepatitis.

Pattern and duration of HBV DNA seropositivity in acute hepatitis B

1988 ◽  
Vol 33 (4) ◽  
pp. 477-480 ◽  
Author(s):  
James R. Wood ◽  
Howard F. Taswell ◽  
Albert J. Czaja ◽  
Dale Rabe
Keyword(s):  
Hepatitis B ◽  
Acute Hepatitis ◽  
Hbv Dna ◽  
Acute Hepatitis B

scholarly journals Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Mary C. Kuhns ◽  
Vera Holzmayer ◽  
Anne L. McNamara ◽  
Mark Anderson ◽  
Gavin A. Cloherty
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Acute Hepatitis ◽  
Quantitative Research ◽  
Hepatitis B Surface Antigen ◽  
Serum Markers ◽  
Hbv Dna ◽  
Highly Sensitive ◽  
B Virus ◽  
Acute Hepatitis B

Abstract Background Hepatitis B virus (HBV) serum markers during typical acute self-limited infection are usually depicted as a composite of traditional HBV markers. The current study updates and expands our knowledge of acute hepatitis B with quantitative molecular and serological data on longitudinal samples from five plasmapheresis donors with acute HBV. Methods 137 longitudinal samples from five plasmapheresis donors with acute HBV were tested, four with self-limited infection and one who developed persistent infection. Testing included quantitative hepatitis B surface antigen (HBsAg), antibodies to HBV antigens, quantitative HBV e antigen (HBeAg), HBV DNA, quantitative HBV core-related antigen (HBcrAg), the highly sensitive ARCHITECT HBsAg NEXT (HBsAgNx) assay, and a quantitative research assay for HBV pregenomic RNA (pg RNA). Results Peak levels of HBV DNA and HBsAg differed by several orders of magnitude among the panels (2.2 × 105–2.7 × 109 IU/ml for HBV DNA and 7.9–1.1 × 105 IU/ml for HBsAg). HBsAg levels peaked an average of 2.8 days after the HBV DNA peak. The overall duration of observed HBsAg positivity was increased by the more sensitive HBsAgNx assay compared to the quantitative assay in four panels. Intermittently detectable low-level HBV DNA was observed after HBsAg loss in three panels. Peak HBeAg levels occurred 2–20 days after the DNA peak and ranged from 1.1 to 4.5 × 103 IU/ml. In four panels with resolution of infection, anti-HBs levels indicating immunity (≥ 10 mIU/ml) were detected 19–317 days after the HBV DNA peak. Maximum HBcrAg concentrations ranged from 1 × 105 to > 6.4 × 106 U/ml and correlated with HBeAg values (R2 = 0.9495) and with HBV DNA values (R2 = 0.8828). Peak pgRNA values ranged from 1.6 × 103 to 1.4 × 108 U/ml and correlated with HBV DNA (R2 = 0.9013). Conclusion Traditional and new/novel HBV biomarkers were used to generate molecular and serological profiles for seroconversion panels spanning the early to late phases of acute HBV. Seroconversion profiles were heterogeneous and may be instructive in appreciating the spectrum of acute profiles relative to the typical composite representation.

scholarly journals The Combination of Nucleotide Analog Therapy and Steroid Pulse Therapy for Acute HBV Infection Effectively Promotes HBV Clearance

2021 ◽  
Vol 13 (1) ◽  
pp. 1-8
Author(s):  
Takeshi Goya ◽  
Tomoyuki Kurashige ◽  
Miho Kurokawa ◽  
Masatake Tanaka ◽  
Tomomi Aoyagi ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Acute Hepatitis ◽  
Pulse Therapy ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Steroid Pulse Therapy ◽  
Therapeutic Effects ◽  
Nucleotide Analogs ◽  
Steroid Pulse ◽  
Acute Hepatitis B

Acute hepatitis B virus (HBV) infection occasionally progresses to acute liver failure, often with poor prognosis. The appropriate pharmacological approach is yet to be established. Although nucleotide analogs (NA) and corticosteroids are candidates for the treatment of acute HBV infection, their therapeutic effects, especially their effect on HBV clearance, remain unclear. To clarify effects on the HBV clearance of combination therapy of NA and steroid pulse therapy (SPT) for acute HBV infection, we first analyze the effectiveness of this therapy in patients with HBV infection compared with NA monotherapy (NAM). Of the 57 consecutive patients with acute hepatitis B infection from May 2007 to December 2018, we have included 25 patients for this study, whom we followed up until HBV clearance. According to the administration of NA and SPT, we divided patients into two groups (NAM group and NA + SPT group) and compared their results. Of the 25 patients, 10 received NAM, whereas 15 received NA + SPT. There were no appreciable adverse effects related to SPT. The time required for the clearance of HBsAg (76 (43–116) days vs. 26 (14–51) days, p = 0.0418) and HBV-DNA (NAM group vs. NA + SPT group: 180 (83.5–220) vs. 69 (43–136) days, p = 0.0420) was significantly shorter in the NA + SPT group than in the NAM group. The hazard ratio of NA + SPT for the clearance of HBsAg and HBV-DNA were 0.45 (0.19–1.09) and 0.35 (0.14–0.89), respectively. In conclusion, we showed that NA + SPT promoted HBV elimination. These findings support the use of the NA + SPT combination for acute HBV infection without the concern of persistent HBV infection.

Sign in / Sign up

Export Citation Format

Share Document